Ekso Bionics Holdings, Inc. Common Stock Q3 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Key Context: The call highlighted a transitional quarter focused on CMS reimbursement progress for the Ekso Indego Personal device, strong international demand offsetting softer U.S. IDN sales, and operational efficiencies. Comparisons below are to the same periods in 2023 unless noted.

Financial Highlights

  • Q3 2024 Revenue: $4.1 million (down from $4.6 million in Q3 2023), impacted by U.S. IDN procurement delays and capital purchase deferrals into Q4 2024/early 2025.
  • Q3 2024 Gross Margin: 53.5% (up slightly from 53.3% in Q3 2023), driven by supply chain cost savings and lower service costs, partially offset by lower-margin distribution sales.
  • Q3 2024 Operating Expenses: $4.8 million (down from $5.4 million in Q3 2023) due to reduced headcount, payroll, and consulting costs.
  • Q3 2024 Net Loss: $2.1 million or $0.10 per share (improved from $3.4 million or $0.24 per share in Q3 2023).
  • 9-Month 2024 Revenue: $12.8 million (down from $13.4 million for the first nine months of 2023); 99 EksoHealth devices sold.
  • 9-Month 2024 Gross Margin: 53% (up from 50% for the first nine months of 2023), benefiting from similar cost efficiencies.
  • 9-Month 2024 Operating Expenses: $15.0 million (down from $18.4 million for the first nine months of 2023).

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call. At this time, all participants are in the listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Steinberg, Finn Partners. Thank you. You may begin. Matt Steinberg : Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; and Jerome Wong, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter ended September 30th, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements include statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involv

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional